Abstract 2298 We previously reported that imatinib treatment could be safely discontinued in
chronic myeloid leukemia (CML) patients who had achieved a sustained complete …

After 5 years of imatinib treatment 40–50% of chronic myeloid leukaemia (CML) patients will
have stable undetectable BCR-ABL by real-time quantitative RT-PCR (RQ-PCR) using strict …

Abstract Abstract 2763 Approximately 50% of CP CML patients achieve complete molecular
response (CMR) at 6–7 years of first-line imatinib therapy. Although imatinib therapy is …

We monitored BCR–ABL transcript levels by quantitative real-time PCR in 103 patients
treated with imatinib for chronic myeloid leukaemia in chronic phase for a median of 30.3 …

Residual disease in chronic myeloid leukemia patients may be assessed by various
molecular methods. After imatinib treatment a significant proportion of patients achieve …

Abstract Abstract 859 Background Imatinib (IM) has greatly improved survival rates in
chronic myeloid leukemia*(* CML). However, all patients (pts) must continue treatment for an …

Most patients (pts) with CML in chronic phase treated with imatinib achieve a major
cytogenetic (CG) remission, and increasing numbers of pts are achieving molecular …

Abstract Abstract 603 Background: Imatinib treatment significantly improves survival in
patients (pts) with CML. We previously demonstrated that Imatinib could be safely …

Real-time quantitative polymerase chain reaction (PCR) for BCR-ABL mRNA in the
peripheral blood (RQ-PCR) provides an accurate and reliable measure of response to …

About 75% of patients with newly diagnosed chronic phase (CP) chronic myeloid leukemia
(CML) treated initially with imatinib achieve complete cytogenetic remission (CCyR), 1 and …